New insights of altered lipid profile in Fragile X Syndrome

Low Levels of HDL in Fragile X Syndrome Patients

(2015) Małgorzata Z. Lisik et al.   LIPIDS

Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open-label study

(2014) Artuela Çaku et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Cholesterol levels in Fragile X syndrome

(2014) Elizabeth Berry-Kravis et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

(2014) Terry A. Jacobson et al.   Journal of Clinical Lipidology

Outcome Measures for Clinical Trials in Fragile X Syndrome

(2013) Elizabeth Berry-Kravis et al.   JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS

Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

(2011) Anna Roubtsova et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Fragile X-associated disorders: a clinical overview

(2011) Anne Gallagher et al.   JOURNAL OF NEUROLOGY

The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis

(2010) Jean Davignon et al.   Current Atherosclerosis Reports

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

(2010) Greg Welder et al.   JOURNAL OF LIPID RESEARCH